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Currently, there are very few reports of the complications of venous stent placement. This article reports the
authors’ experience and provides guidance and recommendations for clinicians on how to treat these com-
plications and how to follow up on patients.Objective/Background: Stent placement in the venous system is an increasingly used treatment modality in
chronic venous obstruction and as additional treatment after thrombolytic therapy in ilio-femoral deep vein
thrombosis (DVT). Experience in treating in-stent thrombosis with ultrasound accelerated catheter directed
thrombolysis (UACDT) is reported.
Methods: A retrospective analysis of patients treated for venous stent occlusion, after percutaneous transluminal
angioplasty (PTA) and stent placement for either chronic venous occlusive disease or persistent vein compression
in patients with acute DVT was performed. Duration of occlusion and suspected clot age were assessed using
patient complaints and typical ﬁndings on duplex ultrasonography (DUS). DUS and venography were used to
assess patency and to determine the cause of re-occlusion. Acute treatment of occlusion was by UACDT.
Additional procedures included PTA, stent placement, and creation of an arteriovenous (AV) ﬁstula.
Results: Eighteen patients (median age 43 years; 67% male), treated for occluded stent tracts with UACDT
between January 2009 and July 2014, were identiﬁed. Indications for initial stenting were treatment of chronic
venous obstructive disease (12 patients) and treatment of underlying obstruction after initial thrombolysis in
acute DVT (six patients). Technical success was achieved in 11/18 (61%) patients. Primary patency in 8/11
patients was 73% at last follow up (median follow up 14 months [range 0e41 months]). Additional treatments
after successful lysis were re-stenting (seven patients) and creation of an AV ﬁstula (six patients).
Conclusion: Treatment with UACDT of recently occluded stent tracts is feasible and effective. Recanalization of
the stent tract can be achieved in most cases. Additional interventions were frequently used after successful
UACDT treatment. Suboptimal stent positioning caused the majority of the stent occlusions.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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During the last two decades endovenous recanalization, by
percutaneous transluminal angioplasty (PTA) and stenting,
in chronic deep venous obstructive disease has quickly
gained in popularity. Many authors have shown excellent
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http://dx.doi.org/10.1016/j.ejvs.2015.01.006clinical success rates.1e3 Because of this, and as stenting
seems to be the only treatment aimed at resolving the
underlying pathology in post-thrombotic syndrome (PTS)
and iliac vein compression syndromes, it has been imple-
mented in many expert venous centers worldwide as a ﬁrst
line treatment. Complication rates have been shown to be
low, with generally no clinically relevant pulmonary emboli
and no procedure related mortality.3e5 The most important
complication is acute re-occlusion of the stented venous
segment, with or without thrombus propagation into
proximal or distal vein tracts. This occurs in 20e30% of
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used.4 In cases of stent re-occlusion return of signs and
symptoms of venous disease can be expected, and in some
cases worsening of complaints compared with the pre-
recanalization state. An important step in preventing re-
occlusion is to guarantee adequate in- and outﬂow for
the stents. Inﬂow problems can arise when veins caudal to
the stented segments are also involved in the post-
thrombotic process, most notably the femoral and deep
femoral vein, as ﬂow volume in such cases might not be
sufﬁcient to maintain patency. Outﬂow problems arise
when venous tracts cephalad to the stents are (partly)
obstructed owing to endoluminal pathology or external
compression. Furthermore, in-stent problems, for example
residual compression by overlying arteries, stenosis, kinking,
or fractures, are also thought to lead to a higher loss of
patency. Prevention by extending stents cephalad or caudal
into a healthy vein tract and using stents that withstand the
pressure from overlying structures such as arteries and do
not kink are therefore very important.6 Adequate antith-
rombotic therapy is also important in preventing re-
thrombosis.
In cases where re-occlusion occurs, removal of as much
of the thrombus load as quickly as possible is generally
thought necessary.7 One possible option is to remove the
thrombus by means of pharmaco-mechanical thrombolysis.
Ultrasound accelerated catheter directed thrombolysis
(UACDT) is used for acute occlusions in the arterial system,
deep vein thrombosis (DVT), and pulmonary embolism.8e11
The literature shows good safety and feasibility for UACDT
for these indications. Possible advantages of UACDT over
the use of a normal thrombolysis catheter are shortened
treatment duration and smaller volumes of thrombolytic
used, reducing the risk of (major) bleeding.12 In the litera-
ture, when there is adequate patient selection, the chance
of achieving technical success is around 90%, together with
a minimal risk of bleeding.13
In this study the experience of treating in-stent throm-
bosis with UACDT in patients referred to a tertiary center is
reported. Furthermore, the pitfalls that have been
encountered in these cases are described, and recommen-
dations are made on how to follow up patients after venous
stenting.
METHODS
Population
From October 2009 to July 2014 all patients treated for
venous stent occlusion by UACDT were eligible for inclusion
in this retrospective analysis. All patients were evaluated for
bleeding risk. Indication for primary stent placement was
either chronic venous obstructive disease or persistent vein
compression in patients with acute ilio-femoral DVT during
thrombolytic therapy. Time between stent placement and
occlusion was assessed and patients were divided into two
groups (within 6 months of stent placement, and longer
than 6 months after stent placement). Occlusion side was
noted and, if available, thrombophilia status was reported.No additional testing for thrombophilia factors was per-
formed. Duration of occlusion and suspected clot age were
assessed from patient complaints and ﬁndings on duplex
ultrasonography (DUS).14 Patient complaints were assessed
and used as the criterion to categorize patients into two
groups: complaints for 21 days, and >21 days. The last
patent duplex scan was taken as a reference value for
assessment of clot age. Stent obstruction was diagnosed
using DUS with normal B-mode settings, power ﬂow, e-ﬂow,
conventional color, and pulse wave Doppler to assess ﬂow
in the stent tract. At least one of the available modalities or
combinations was used. The venous tract was assessed in
both transverse and longitudinal planes. In order to visu-
alize ﬂow in the stented ilio-caval tract a number of ﬂow
augmenting maneuvers were performed, such as inspiration
and expiration, dorsiﬂexion of the foot, and gluteal muscle
contraction.
Before recanalization and catheter placement, venog-
raphy was routinely performed to conﬁrm the diagnosis of
stent obstruction.
Dutch law allows for retrospective analysis of patient
data without speciﬁc approval of an ethical committee.
Intervention
The interventional radiologist placed the UACDT catheter
under venographic control. The EKOS Endowave Peripheral
Lysis System (BTG International Ltd, London, UK) consists of
a multilumen infusion catheter with removable, coaxial ul-
trasound (US) cores and a control unit that simultaneously
delivers high-frequency (2.2 MHz), low energy (0.45 W) US
energy and thrombolytic drug into the thrombus. All pa-
tients received UACDT with the EKOS Endowave system.
Urokinase (Medacinase, Lamepro, the Netherlands) was
used as the thrombolytic agent in all cases. Urokinase was
administered at 100,000 units/hour after a single bolus of
250,000 units at the start of treatment. In cases of bilateral
occlusion, two catheters were inserted and the drug dosage
was evenly divided over the two catheters, each with their
own EKOS machine. During thrombolysis ﬁbrinogen, he-
moglobin, activated partial thromboplastin time (APTT),
prothrombin time standardized to international normalized
ratio (INR), thrombocytes, and D-dimer levels were
routinely monitored. During active thrombolysis, anticoag-
ulant treatment was substituted by intravenous unfractio-
nated heparin guided by APTT (between 40 and 60 seconds
or 1.2e1.7-fold the reference value of 34 seconds). At the
same time, patients were ﬁtted with intermittent pneu-
matic compression sleeves. Inferior vena cava ﬁlters are not
used routinely at the authors’ hospital. None of the patients
received a caval ﬁlter. After thrombolysis, patients either
resumed or started oral anticoagulation for at least 6
months or, if indicated, for life (recurrent DVT). Adequate
anticoagulation was achieved with either Coumadin (Bris-
tol-Myers Squibb, New York, NY, USA) with an INR between
2.5 and 3.5, according to the standards of the Dutch
Federation of Thrombosis Services, or rivaroxaban 20 mg
once daily. The choice of anticoagulant agent was based on
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offered to patients and worn based on the preference of
the patient. Mobilization was encouraged.
Assessment of recanalization
Phlebography was performed daily to monitor thrombolysis
progression and to evaluate obstructions in the venous
outﬂow tract. Duration of thrombolysis was determined by
assessment of phlebographic imaging and the point where
>90% lysis of the clot had been achieved.15 Because of
bridging towards additional treatment, thrombolysis was
continued in a number of cases. Determination of the cause
of the stent thrombosis by means of phlebography from
multiple angles was attempted. In some cases cone beam
computed tomography was used to create a three dimen-
sional reconstruction of the stent tract. If the reason for
thrombosis of the tract was identiﬁed, adequate measures
were taken to resolve the problem and prevent future re-
thrombosis. Objective identiﬁcation of the underlying
cause of stent thrombosis was only possible in patients with
successful thrombolysis.
Additional procedures
After successful UACDT procedures, patients received
additional interventions if indicated. Additional procedures
were performed as soon as possible after successful
thrombolysis. Additional procedures such as PTA with or
without re-stenting were performed by the interventional
radiologist. Surgical procedures to increase inﬂow such as
construction of an AV-ﬁstula between the common femoral
vein and artery or endophlebectomy were performed by
the vascular surgeon. Self expandable stents for stenting of
underlying obstructions were used (sinus-XL and sinus-
Venous [Optimed, Ettingen, Germany] and Zilver vena
[Cook, Bloomington, IN, USA]). Various diameters and
lengths of stent were used ranging from 12 to 26 mm in
diameter and from 60 to 150 mm in length. Stent sizes were
determined by multiplanar venography.
Complications
Complications following thrombolysis and follow up were
categorized into groups. These included bleeding compli-
cations, pulmonary embolism (PE), recurrent thrombosis,
infections, and others. Bleeding was classiﬁed as major if it
was overt, with a fall in hemoglobin of 2 g/dL, or when
hemorrhage led to transfusion of two units of packed red
blood cells or whole blood. Bleeding situated in a critical
organ (intracranial, retroperitoneal or pericardial) or if it
contributed to death was also deﬁned as major bleeding.
Bleeding was classiﬁed as minor if it was situated near the
catheter insertion site.
Follow up
Standardized follow up was performed. Patients returned at
2 weeks, 6 weeks, 3 months, 6 months, 1 year, and annually
thereafter. If the patient experienced complaints, follow upwas performed at the earliest convenience, usually the
same or next day. During follow up patency of the stent
tract was assessed using DUS. A dedicated sonographer
performed DUS. Recurrence, re-treatment, PE, and other
complications were recorded.
Routine follow up after stenting was standardized in this
manner: the day after stenting, patients were checked with
DUS to ensure patency of the tract prior to discharge. At 2
weeks, 6 weeks, 3 months, and 6 months after stenting the
patients were seen with clinical follow up and routine DUS
examination. The complete stented tract was visualized in
every patient. Apparent thrombosis and/or lack of ﬂow in
the stented tract were used to determine patency.
RESULTS
Patients
A total of 19 legs in 18 patients were treated with UACDT
for venous stent thrombosis. The majority of patients were
male. At the time of thrombolysis the average age was 43
years. In 33% of cases the initial indication for stent
placement was an underlying stenosis after acute ilio-
femoral DVT treatment with UACDT. The remaining 67%
received PTA and stenting as a treatment for chronic deep
venous obstruction and subsequent complaints. Most (67%)
stents were placed in the left iliac tract. Most (83% of pa-
tients) stent occlusions occurred within 6 months of their
initial placement. In 13 (72%) patients the duration of
complaints was assessed. In the other cases it was not
possible to make an assessment of duration of complaints,
either because of their vagueness or absence. Eleven pa-
tients were assessed as having acute thrombosis (<21 days,
according to the reporting standards in venous disease).
Patient characteristics are summarized in Table 1.
Before the UACDT to treat the in-stent re-thrombosis,
patients had received a median of three (range 1e13)
stents in 1e3 stenting sessions. This was done on the left
side in 13, on the right side in one, and bilaterally in three
cases; one patient only had stents placed in the inferior
vena cava. In all patients Nitinol self expandable stents were
used (sinus XL, sinus repo-visual, sinus Venous); in two
cases these were combined with WALLSTENTs (Boston Sci-
entiﬁc, Marlborough, MA, USA), and in one case with
balloon expandable stents (Andramed, Reutlingen,
Germany).
Table 1 shows the baseline characteristics of the patients.
Treatment results and additional procedures
All patients underwent UACDT with the EKOS catheter.
Catheter placement was successful in all cases. In 11/18
patency was successfully restored. This resulted in a tech-
nical success rate of 61%. All patients with failed throm-
bolysis had an unknown or estimated clot age of >21 days
and last patent duplex >21 days previously. Median lysis
time of successfully lysed cases was 19 hours (range 11e
101 hours). In ﬁve cases additional stenting was performed
and an arteriovenous (AV) ﬁstula created to treat an
Table 1. Patient characteristics (n ¼ 18).
Sex, male 12 (67)
Age (y), mean  SD (range) 43  15 (15e75)
DVT history
First DVT 10 (56)
Recurrent DVT 8 (44)
Primary stent indication
Acute ilio-femoral DVT 6 (33)
Chronic venous obstruction 12 (67)
Original location stents
Left iliac tract 13 (73)
Right iliac tract 1 (5)
Inferior vena cava 1 (5)
Inferior vena cava þ left and right iliac
tract
3 (17)
Time between stent placement and stent occlusion
<6 months 15 (83)
6 months 3 (17)
Occlusion side
Left iliac tract 12 (67)
Right iliac tract 2 (11)
Inferior vena cava 4 (22)
Thrombophilia (seven patients tested)a
Positive 5 (28)
Negative 2 (11)
Not tested 11 (61)
Estimated clot age
21 days 11 (61)
>21 days 3 (17)
Unclear 4 (22)
Days until last patent duplex
21 8 (44)
>21 10 (56)
Note. Values are given as n (%) unless otherwise stated.
a Encountered thrombophilia: factor V Leiden, antithrombin deﬁ-
ciency, protein C deﬁciency, antiphospholipid syndrome.
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previously. Figs. 1 and 2 show pre- and post-thrombolysis
results. Furthermore, stent related occlusions and insufﬁ-
cient inﬂow in the stent tract were encountered. In twoFigure 1. (A) In situ sinus venous stent in the left common iliac vein.
femoral vein shows contrast ﬁlling of the external and internal iliac
vein. (C) Recanalization of the stent with outﬂow of contrast to the
Lysis System (BTG International Ltd, London, UK) thrombolysis cathecases additional stenting was performed, and in one patient
inﬂow to the stent tract was secured by creation of an AV
ﬁstula. In total, 8/11 (73%) patients needed ancillary in-
terventions after successful thrombolysis. In all cases of
UACDT the underlying cause of re-thrombosis was identi-
ﬁed. These were suboptimal positioning, failure due to stent
characteristics (kinking of stents and stent fracture), insuf-
ﬁcient inﬂow, or inadequate anticoagulation. Fig. 3 shows
an example of stent fracture in the venous system. Most
occlusions encountered were related to stent failure and
suboptimal positioning. Table 2 shows the treatment re-
sults. Table 3 shows the time between last patent duplex
and occlusion, suspected clot age, and suspected reason for
re-occlusion.
Complications
Six patients experienced adverse events. During UACDT two
had a fall in hemoglobin without a bleeding focus, which
necessitated transfusion. One patient had minor bleeding at
the catheter insertion site, which was solved by manual
compression. One patient experienced heparin induced
thrombocytopenia. Heparin was switched for intravenous
argatroban for the further duration of UACDT. One patient
complained of blepharoedema and urticaria, which was
recognized as an allergic reaction to the iodine contrast
used for venography unrelated to thrombolytic therapy.
One patient had fever with positive blood cultures during
thrombolysis. In this patient thrombolysis was stopped and
treatment with antibiotics started. None of the patients
experienced multiple complications. There were no clinically
relevant pulmonary emboli or treatment related mortality.
Table 4 gives an overview of all complications encountered
during UACDT.
Follow up
Of the successfully lysed patients (n ¼ 11), eight remained
patent, a primary patency of 73%. Seven patients experi-
enced complete relief of complaints and two had partial(B) Digital subtraction venography with the catheter in the common
veins. There is no ﬁlling of the (occluded) stent in the common iliac
inferior vena cava. (D) Placement of the EKOS Endowave Peripheral
ter through the occluded stent.
Figure 2. (A) Control venography after extended thrombolysis and balloon angioplasty shows an open lumen with outﬂow to the inferior
vena cava. (B) Extension of the stented deep vein tract to the inferior vena cava and external iliac vein to cover the entire deep vein
obstruction. (C) Control venography after stenting and balloon angioplasty shows improved (out) ﬂow through the iliac veins with
persistent ﬁlling of presacral collaterals. (D) Final control venography after additional balloon angioplasty shows adequate ﬂow from the
groin to the inferior vena cava without ﬁlling of collaterals.
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case, due to stent related problems, there was an imme-
diate re-occlusion the day after successful lysis. Table 5
shows the follow up data for the successfully lysed patients.
DISCUSSION
With the growing number of effective thrombolytic treat-
ments in acute ilio-femoral DVT, it is expected that an
increasing number of patients will also be stented for re-
sidual stenotic lesions. Some reports show that >50% of
patients are stented after thrombolysis.16 At the same time,Figure 3. Fractures of the rigid Sinus XL stents in the distal external
iliac vein/proximal common femoral vein are seen (arrow).there are also more interventions performed in patients
with PTS due to extensive chronic occlusions in the ilio-caval
tract. As both of these procedures gain in popularity, it can
be expected that more venous stenting related complica-
tions will be encountered.
In this study, re-occlusion was identiﬁed to be the most
frequent and clinically important complication after venous
stenting, and, to the authors’ knowledge, this is the ﬁrst
study to focus speciﬁcally on how to treat this important
complication. Earlier studies also highlighted stent occlu-
sions to be an important complication after venous
stenting.4,5,17
A technically successful recanalization of occluded stents
in the venous system of 61% and a primary patency of 73%
after a median follow up of 12 months is reported here. In
all cases it was possible to get a wire across the occluded
segment. In all cases the intention was to treat stent oc-
clusion with a suggested thrombus age of <21 days based
on complaints or homogenicity on DUS. In this series,
thrombolysis within 21 days seemed to result in more
success than interventions performed at a later stage.
Although there is one report on successful interventions in
the chronic DVT phase,18 it was not possible to reproduce
these ﬁndings in the current study. It is important to assess
the time of onset of the thrombosis accurately. It was found
Table 2. Ultrasound accelerated catheter directed thrombolysis
(UACDT; n ¼ 18).
Successful thrombolysis?
Yes 11 (61)
No 7 (39)
Median (range) duration of successful
thrombolysis (h) (n ¼ 11)
19 (11e101)
Re-stenting after successful UACDT (n ¼ 11) 7 (64)
Other additional interventions after successful UACDT (n ¼ 11)
Arteriovenous ﬁstula 6 (55)
Note. Values are given as n (%) unless otherwise stated.
Table 3. Time between last patent duplex and occlusion, suspected clot age, and suspected reason for re-occlusion.
Patient Days since last
patent duplex
Suspected clot
age (d)
Lysis successful? Reason for occlusiona
1 120 21 Yes Stent related failurea
2 15 21 Yes Stent related failurea, suboptimal stent position
3 5 21 Yes Stent related failurea
4 0 21 Yes Inadequate inﬂow
5 9 21 Yes Stent related failurea
6 9 21 Yes Stent related failurea, suboptimal stent position
7 5 21 Yes Stent related failurea, suboptimal stent position
8 42 21 Yes Stent related failurea
9 10 21 Yes Stent related failurea, suboptimal stent position
10 41 21 Yes Suboptimal stent position, failed anticoagulation
11 21 21 Yes Inadequate inﬂow
12 56 Unknown No Stent related failurea
13 83 Unknown No Stent related failurea
14 120 Unknown No Stent related failurea
15 40 >21 No Stent related failurea, suboptimal stent position
16 35 Unknown No Stent related failurea
17 30 >21 No Stent related failurea
18 93 >21 No Stent related failurea
a For example, stent fracture, kinking, implosion.
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complaints was not useful in determining thrombus age and
therefore the success rate of the thrombolysis was not
predictable. Other techniques, such as magnetic resonance
venography, DUS elastography, or intravascular ultrasound,
might prove more useful in determining thrombus age,
better predict outcome, and be used for patient selection.19
Regarding the speciﬁc usefulness of UACDT in regaining
patency, a median time to lysis of 90% of the thrombus of
19 hours was found in the current study, which is fairly
quick. However, in some cases lysis treatment was
continued until the necessary additional procedures could
be performed.
Two rare complications were encountered: heparin
induced thrombocytopenia and contrast allergy. There were
two major cases of hemorrhage requiring transfusion. Other
complications involved catheter insertion site bleeding,
which were very minor; therefore, it may be concluded that
UACDT is a safe procedure.
Many stent related ﬂow complications result in re-
occlusion of the venous tract. Occlusion of the stent tract
nulliﬁes the progress gained by the initial treatment. When
encountered at an early stage, the thrombosed stent tractTable 4. Complications encountered during ultrasound accelerated
catheter directed thrombolysis.
Complication n (%)
Minor bleedinga 1 (5)
Major bleedingb 2 (11)
Pulmonary embolism 0 (0)
Death 0 (0)
Otherc 3 (17)
Note. Patients (n ¼ 18).
a Epistaxis, catheter insertion site.
b Drop in hemoglobin needing red blood cell transfusion.
c Allergic reaction, infection, heparin induced thrombocytopenia.can be cleared by thrombolysis.4 Patency can be regained
and, most importantly, the underlying cause of occlusion
can be identiﬁed or should be identiﬁed during the proce-
dure. UACDT is one of the available options for regaining
patency. Other clot removal therapies can also be used for
this purpose.20
In all cases of successful thrombolysis the underlying
cause of the occlusion was identiﬁed. Also, in the group that
did not have successful thrombolysis, stent related causes
for occlusion were identiﬁed. In total, in 15/18 cases, stent
related failures such as kinking, fracture, and continuous
compression of the stents were encountered. These stent
related problems are potentially due to the stent charac-
teristics. The stents used in this study are primarily designed
for arterial use. With new, dedicated venous stents future
stent related occlusions are expected to be prevented.
Ideally, dedicated venous stents with high ﬂexibility, high
radial force, and large diameters are used in the venous
system.21 A number of dedicated venous stents are now
commercially available.
Most of the occlusions occurred within 6 months of the
initial stenting. Strict follow up of patients is therefore
paramount. The frequent follow ups allowed for timely in-
terventions with UACDT to prevent re-occlusion. At the 6Table 5. Follow up data for the successfully lysed patients (n¼ 11).
Median follow up (range) (mo) 12 (0e41)
Patency at follow up
Patent 8 (73)
Occluded 3 (27)
Relief of complaints
Complete relief 7 (64)
Partial relief 2 (18)
No relief 1 (9)
unknown 1 (9)
Note. Values are given as n (%) unless otherwise indicated.
446 R.H.W. Strijkers et al.month visit continuation of anticoagulation was evaluated
based on stent conﬁguration, patient risk factors, and pa-
tient preference. Thrombocyte aggregation inhibitors were
not routinely prescribed following cessation of Coumadin,
although they might be of inﬂuence. If at any point be-
tween follow up visits patients experienced complaints,
they were seen at the earliest convenience. After 6 months,
follow up visits were planned at 1 year and annually
thereafter, depending on patient preference.
The most difﬁcult problem encountered in this study
involved patients with poor inﬂow due to extensive chronic
venous occlusive disease with scarring in both major inﬂow
vessels (i.e., femoral and deep femoral vein.). Currently,
there are no reported successful treatments available for
these veins. Endophlebectomy with or without AV ﬁstula
has been described in the literature as a treatment op-
tion.22e24 Stenting might be a possibility for these veins
however, the currently available options are not suitable for
placement in the femoral or deep femoral tract. To ensure
adequate inﬂow, the creation of a temporary AV ﬁstula,
with or without an endophlebectomy of the common
femoral vein, is currently relied upon.25 Further research is
needed to improve care in these cases.
One of the drawbacks of this study is its retrospective
nature. The expected number of cases per center per year is
expected to be very low, which makes it challenging to
complete a prospective study. Optimal registration of pa-
tient data and pooling of results from retrospective studies
could improve patient care considerably. Therefore, other
centers should be encouraged to report their experience
regarding stent thrombosis and treatment.
CONCLUSION
Treatment with UACDT of occluded stent tracts is feasible
and effective. Recanalization of the stent tract can be ach-
ieved in some cases with recent thrombosis <21 days.
Additional interventions were frequently necessary after
successful UACDT treatment. Most stent occlusions were
caused by stent related problems.
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